Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Guillain-Barré Syndrome (GBS), a condition where the immune system attacks the nerves, based on specific recognised diagnostic guidelines.
- People whose muscle weakness caused by GBS started no more than 10 days before the first treatment infusion in the trial.
- People whose GBS symptoms are rated as moderately to severely disabling at the screening stage, based on a standard GBS disability scale (scores of 3, 4, or 5 out of 5).
Who may not be able to join:
- People who have already received, or are planned to receive, plasma exchange therapy or intravenous immunoglobulin (a type of antibody treatment given through a drip) for their GBS.
- People who have been diagnosed with a variant form of GBS, including conditions such as Miller Fisher syndrome, Bickerstaff's encephalitis, or related overlap syndromes, rather than standard GBS.
Important: Other criteria set out in the trial protocol may also apply. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Annexon, Inc.
Phone: 1-650-822-5500
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Area Under the Tanruprubart Serum Concentration-time Curve to the Last Sample (AUC0-t); Observed Time to Maximum Observed Serum Concentration (Cmax) (Tmax) of Tanruprubart
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.